Arecor Ltd has inked a further collaboration agreement with a top five pharmaceutical company to develop a liquid formulation of a ready-to-administer (RTA) medicine using its Arestat technology.
The biopharma group said its partner will fund a feasibility study into the formula and will retain an exclusive option to a global royalty bearing licence for the product and Arecor’s associated IP.
READ: Arecor signs agreement with Hikma Pharma to develop new injectable medicine
"This is the second RTA collaboration that we have announced in recent weeks involving our proprietary technology platform Arestat. It is a further project for an existing pharmaceutical partner which demonstrates the value of our technology and expertise together with the strength of our commercial relationships”, said Arecor chief executive Sarah Howell.